Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Accounts Payable & Accrued Expense : ¥206 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Accounts Payable & Accrued Expense?

Hunan Er-Kang Pharmaceutical Co's quarterly accounts payable & accrued expense declined from Sep. 2023 (¥196 Mil) to Dec. 2023 (¥187 Mil) but then increased from Dec. 2023 (¥187 Mil) to Mar. 2024 (¥206 Mil).

Hunan Er-Kang Pharmaceutical Co's annual accounts payable & accrued expense increased from Dec. 2021 (¥207 Mil) to Dec. 2022 (¥267 Mil) but then declined from Dec. 2022 (¥267 Mil) to Dec. 2023 (¥187 Mil).

Hunan Er-Kang Pharmaceutical Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Accounts Payable & Accrued Expense Chart

Hunan Er-Kang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

204.61

254.92

207.25

267.15

187.31

Hunan Er-Kang Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															232.37	227.75	195.73	187.31	205.52

Hunan Er-Kang Pharmaceutical Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Accounts Payable & Accrued Expense

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines